Shares of Eagle Pharmaceuticals EGRX were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share were up 63.16% year over year to $0.93, which beat the estimate of $0.80.
Revenue of $48,124,000 up by 14.75% from the same period last year, which beat the estimate of $45,860,000.
Looking Ahead
Eagle Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 09, 2021
Time: 08:30 AM
Recent Stock Performance
Company's 52-week high was at $53.43
Company's 52-week low was at $36.48
Price action over last quarter: Up 15.29%
Company Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.